Abbott settles large part of US Tricor antitrust litigation
This article was originally published in Scrip
Abbott Laboratorieshas agreed to pay $184 million to settle antitrust litigation with direct purchasers (ie, retailers, wholesalers) and certain individual plaintiffs over formulation changes to the company's branded hypolipaemic Tricor (micronised fenofibrate), according to a filing with the US Securities and Exchange Commission. The plaintiffs, which included Teva Pharmaceutical Industries, alleged that, as generic companies were developing ANDAs for Tricor, Abbott responded by changing the formulation of the product, not to improve the product but simply to prevent generic formulations from becoming AB-rated for substitution with Tricor. Other similar suits filed by over a dozen state attorneys general remain outstanding (Scrip Online, April 2nd, 2008). Abbott denies wrongdoing, but said it settled to avoid the uncertainty of a trial outcome. Abbott has continuously maintained that all of the suits are without merit, and that it has provided patients with continuous improvements to Tricor – an approach that is perfectly legal.
You may also be interested in...
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.